R. You

发表

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study *

B. Elewski, K. Reich, M. Augustin, 2020, The British journal of dermatology.

Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32‐week results from the randomized placebo‐controlled TRANSFIGURE trial

K. Reich, M. Augustin, U. Mrowietz, 2019, The British journal of dermatology.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate‐to‐severe plaque psoriasis up to 1 year: Results from the CLEAR study

F. Vanaclocha, K. Reich, A. Blauvelt, 2017, Journal of the American Academy of Dermatology.

Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study

T. Luger, U. Mrowietz, R. Bissonnette, 2017, The British journal of dermatology.

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial

A. Gottlieb, A. Kubanov, J. Sullivan, 2017, Journal of the American Academy of Dermatology.

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)

C. Paul, C. Papavassilis, J. Lacour, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial *

K. Reich, M. Augustin, G. Bruin, 2022, The British journal of dermatology.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.

F. Vanaclocha, K. Reich, A. Blauvelt, 2015, Journal of the American Academy of Dermatology.

Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.

I. Hampele, K. Reich, J. Szepietowski, 2022, The British journal of dermatology.

Sustained efficacy of secukinumab in patients with moderate‐to‐severe palmoplantar psoriasis: 2·5‐year results from GESTURE, a randomized, double‐blind, placebo‐controlled trial

A. Gottlieb, K. Papp, A. Kubanov, 2020, The British journal of dermatology.

Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on Control

B. Bieth, S. Weber, M. Vandemeulebroecke, 2021, Clinical pharmacology and therapeutics.